Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre Clinical Trial of Switching Between Intravitreal Bevacizumab (Avastin®) and Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema (SwitchDMO)

NCT01787669 is registered in ClinicalTrials.gov with University of Sydney as lead sponsor.

NCT NCT01787669
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01787669 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre Clinical Trial of Switching Between Intravitreal Bevacizumab (Avastin®) and Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema (SwitchDMO)
Lead sponsor
University of Sydney
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2013
Completion date
October 31, 2017
Enrollment
19 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetic macular edema, diabetic macular oedema, diabetic retinopathy